NanoViricides (NNVC) 10-Q 14 Nov 17 2018 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Sep. 30, 2017	Nov. 14, 2017
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2017
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q1
Entity Registrant Name	NANOVIRICIDES, INC.
Entity Central Index Key	1,379,006
Current Fiscal Year End Date	--06-30
Entity Filer Category	Non-accelerated Filer
Trading Symbol	NNVC
Entity Common Stock, Shares Outstanding		63,335,000

Balance Sheets

Balance Sheets - USD ($)	Sep. 30, 2017	Jun. 30, 2017
CURRENT ASSETS:
Cash and cash equivalents	$ 13,512,240	$ 15,099,461
Prepaid expenses	192,420	190,166
Total Current Assets	13,704,660	15,289,627
PROPERTY AND EQUIPMENT
Property and equipment	13,806,994	13,776,561
Accumulated depreciation	(2,671,690)	(2,505,501)
Property and equipment, net	11,135,304	11,271,060
TRADEMARK AND PATENTS
Trademark and patents	458,954	458,954
Accumulated amortization	(77,824)	(75,756)
Trademark and patents, net	381,130	383,198
OTHER ASSETS
Security deposits	3,515	3,515
Service agreements	41,157	55,414
Other Assets	44,672	58,929
Total Assets	25,265,766	27,002,814
CURRENT LIABILITIES:
Accounts payable	90,359	135,786
Accounts payable - related parties	818,783	340,695
Accrued expenses	34,192	34,004
Deferred interest payable - current portion	125,000	166,667
Total Current Liabilities	5,283,932	4,665,518
LONG TERM LIABILITIES:
Total Long Term Liabilities	1,462,625	2,015,354
Total Liabilities	6,746,557	6,680,872
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS’ EQUITY:
Common stock, $0.001 par value; 150,000,000 shares authorized, 63,335,194 and 63,306,774 shares issued and outstanding at September 30, 2017 and June 30, 2017, respectively	63,333	63,305
Additional paid-in capital	95,585,765	95,382,979
Accumulated deficit	(77,134,246)	(75,128,691)
Total Stockholders' Equity	18,519,209	20,321,942
Total Liabilities and Stockholders' Equity	25,265,766	27,002,814
Warrant [Member]
LONG TERM LIABILITIES:
Derivative liability - warrants	1,462,625	2,015,354
Series C Debentures [Member]
CURRENT LIABILITIES:
Debentures payable - Series C, net of discount	4,195,504	3,956,153
Derivative liability - Series C debentures	20,094	32,213
Series A Convertible Preferred Stock [Member]
STOCKHOLDERS’ EQUITY:
Series A Convertible Preferred stock, $0.001 par value, 8,500,000 shares designated, 4,356,460 and 4,348,744 shares issued and outstanding, at September 30, 2017 and June 30, 2017, respectively	$ 4,357	$ 4,349

Balance Sheets _Parenthetical_

Balance Sheets [Parenthetical] - $ / shares	Sep. 30, 2017	Jun. 30, 2017
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	63,335,194	63,306,774
Common stock, shares, outstanding	63,335,194	63,306,774
Series A Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	8,500,000	8,500,000
Preferred stock, shares issued	4,356,460	4,348,744
Preferred stock, shares outstanding	4,356,460	4,348,744

Statements of Operations

Statements of Operations - USD ($)	3 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
OPERATING EXPENSES
Research and development	$ 1,155,228	$ 1,452,137
General and administrative	1,075,218	988,312
Total operating expenses	2,230,446	2,440,449
LOSS FROM OPERATIONS	(2,230,446)	(2,440,449)
OTHER INCOME (EXPENSE):
Interest income	24,394	14,176
Interest expense	(125,000)	(245,000)
Discount on convertible debentures	(239,351)	(403,462)
Change in fair value of derivatives	564,848	13,291
Other income (expense), net	224,891	(620,995)
LOSS BEFORE INCOME TAXES	(2,005,555)	(3,061,444)
INCOME TAX PROVISION	0	0
NET LOSS	$ (2,005,555)	$ (3,061,444)
NET LOSS PER COMMON SHARE
- Basic (in dollars per share)	$ (0.03)	$ (0.05)
- Diluted (in dollars per share)	$ (0.03)	$ (0.05)
Weighted average common shares outstanding
- Basic (in shares)	63,307,083	58,179,949
- Diluted (in shares)	63,307,083	58,179,949

Statement of Changes in Stockho

Statement of Changes in Stockholders' Equity - 3 months ended Sep. 30, 2017 - USD ($)	Total	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	AccumulatedDeficit [Member]
Balance at Jun. 30, 2017	$ 20,321,942	$ 4,349	$ 63,305	$ 95,382,979	$ (75,128,691)
Balance (in shares) at Jun. 30, 2017		4,348,744	63,306,774
Series A Preferred stock issued for employee stock compensation	158,799	$ 8	$ 0	158,791	0
Series A Preferred stock issued for employee stock compensation (in shares)		7,716	0
Common stock issued for consulting and legal services rendered	27,000	$ 0	$ 20	26,980	0
Common stock issued for consulting and legal services rendered (in shares)		0	20,062
Warrants issued to Scientific Advisory Board	5,773	$ 0	$ 0	5,773	0
Common shares issued for Directors fees	11,250	$ 0	$ 8	11,242	0
Common shares issued for Directors fees (in shares)		0	8,358
Net loss	(2,005,555)	$ 0	$ 0	0	(2,005,555)
Balance at Sep. 30, 2017	$ 18,519,209	$ 4,357	$ 63,333	$ 95,585,765	$ (77,134,246)
Balance (in shares) at Sep. 30, 2017		4,356,460	63,335,194

Statements of Cash Flows

Statements of Cash Flows - USD ($)	3 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (2,005,555)	$ (3,061,444)
Adjustments to reconcile net loss to net cash used in operating activities
Preferred shares issued as compensation	158,799	182,898
Common shares issued as compensation and for services	38,250	38,250
Warrants granted to Scientific Advisory Board	5,773	17,148
Depreciation	166,189	163,286
Amortization	2,068	2,067
Change in fair value of derivative liability	(564,848)	(13,291)
Amortization of debt discount on convertible debentures	239,351	403,462
Changes in operating assets and liabilities:
Prepaid expenses	(2,254)	11,895
Other assets	14,257	8,678
Accounts payable	(45,427)	172,864
Accounts payable - related party	478,088	(109,015)
Accrued expenses	188	47
Deferred interest payable	(41,667)	(41,668)
NET CASH USED IN OPERATING ACTIVITIES	(1,556,788)	(2,224,823)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(30,433)	(24,435)
CASH FLOWS FROM FINANCING ACTIVITIES:
NET CHANGE IN CASH AND CASH EQUIVALENTS	(1,587,221)	(2,249,258)
Cash and cash equivalents at beginning of period	15,099,461	24,162,185
Cash and cash equivalents at end of period	13,512,240	21,912,927
SUPPLEMENTAL DISCLOSURE OF CASH FLOWS INFORMATION:
Interest paid	$ 166,667	$ 286,667

Organization and Nature of Busi

Organization and Nature of Business	3 Months Ended
	Sep. 30, 2017
Organization, Consolidation and Presentation Of Financial Statements [Abstract]
Nature of Operations [Text Block]	Note 1 - Organization and Nature of Business NanoViricides, Inc. (the “Company”) was incorporated under the laws of the State of Colorado on July 25, 2000 Edot-com.com, Inc . May 12, 2005 ., On June 1, 2005, Edot-com.com, Inc. (“ECMM”) acquired NanoViricides, Inc., a privately owned Florida corporation (“NVI”), pursuant to an Agreement and Plan of Share Exchange (the “Exchange”). NanoViricides, Inc. was incorporated under the laws of the State of Florida on May 12, 2005. Pursuant to the terms of the Exchange, ECMM acquired NVI in exchange for an aggregate of 80,000,000 100,000,000 4,000 As a result of the Exchange transaction, the former NVI stockholders held approximately 80 On June 28, 2005, NVI was merged into its parent ECMM and the separate corporate existence of NVI ceased. Effective on the same date, Edot-com.com, Inc. changed its name to NanoViricides, Inc. and its stock symbol to “NNVC”, respectively. NanoViricides, Inc. is a nano-biopharmaceutical company whose business goals are to discover, develop and commercialize therapeutics to advance the care of patients suffering from life-threatening viral infections. NanoViricides is unique in the bio-pharma field in that it possesses its own state of the art facilities for the design, synthesis, analysis and characterization of the nanomedicines that we develop, as well as for production scale-up, and c-GMP-like production in quantities needed for human clinical trials. The biological studies such as the effectiveness, safety, bio-distribution and Pharmacokinetics/Pharmacodynamics on our drug candidates are performed by external collaborators and contract organizations. We are a company with several drugs in various stages of early development. Our drugs are based on several patents, patent applications, provisional patent applications, and other proprietary intellectual property held by TheraCour Pharma, Inc. (“TheraCour”), to which we have the necessary exclusive licenses in perpetuity. The first agreement we executed with TheraCour on September 1, 2005, gave us an exclusive, worldwide license for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Herpes Simplex Virus (HSV), Influenza and Asian Bird Flu Virus. Under the License Agreements, TheraCour Pharma will receive a royalty upon sale of resulting products from NanoViricides. There is no royalty payable to date. On February 15, 2010 the Company executed an Additional License Agreement with TheraCour. Pursuant to the Additional License Agreement, the Company was granted exclusive licenses, in perpetuity, for technologies, developed by TheraCour, for the development of drug candidates for the treatment of Dengue viruses, Ebola/Marburg viruses, Japanese Encephalitis, viruses causing viral Conjunctivitis (a disease of the eye) and Ocular Herpes. As consideration for obtaining these exclusive licenses, we agreed to pay a onetime licensing fee equal to 2,000,000 shares (adjusted for the 3.5 to 1 reverse split) 2,000,000 2,000

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Sep. 30, 2017
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	Note 2 - Summary of Significant Accounting Policies The accompanying unaudited interim financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission for Interim Reporting. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim financial statements furnished reflect all adjustments (consisting of normal recurring accruals) that are, in the opinion of management, considered necessary for a fair presentation of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. The accompanying financial statements and the information included under the heading “Management’s Discussion and Analysis or Plan of Operation” should be read in conjunction with our Company’s audited financial statements and related notes included in our Company’s Form 10-K for the fiscal year ended June 30, 2017 filed with the SEC on September 28, 2017. For a summary of significant accounting policies, see the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2017 filed on September 28, 2017. Basic net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock and potentially outstanding shares of common stock during the period to reflect the potential dilution that could occur from common shares issuable through stock options, warrants, convertible preferred stock, and convertible debentures. Potentially Outstanding Dilutive Common Shares For the For the Three Months Three Months Ended Ended September 30, 2017 September 30, 2016 Warrants 6,685,292 6,633,848 Total potentially outstanding dilutive common shares 6,685,292 6,633,848 Pursuant to the redemption provisions of the Company’s Series C Convertible Debenture (the “Series C Debenture”), the Company, at its sole option, shall have the right, but not the obligation, to repurchase the Debenture at any time prior to the Maturity Date (the “Redemption”). If the Company intends to repurchase the Debenture, and if the closing bid price of the common Stock is greater than $5.25 on the Redemption Date, unless the Holder, on or prior to the Redemption Date, elects to receive the “Redemption Payment”, as that term is defined herein, the Company shall pay to the Holder: (i) 952,381 shares of common stock in consideration of the exchange of the principal amount of the Debenture; and (ii) any and all accrued coupon interest. If on or prior to the Redemption Date, the Holder elects to receive the Redemption Payment, or the closing bid price of the Common Stock is less than $5.25, the Company shall issue to the Holder: (i) the principal amount of the Debenture; (ii) any accrued coupon interest; (iii) additional interest of 7% per annum for the period from the date of issuance of the Debenture to the Redemption Date; and (iv) warrants to purchase 619,048 shares of common stock which shall expire in three years from the date of issuance at an exercise price of $6.05 per share of common stock (the “Redemption Warrants”, and collectively with (i) – (iv), the “Redemption Payment”). The Company shall use its best efforts to register the shares underlying the Redemption Warrants under a “shelf” registration statement, provided same is available to the Company, in accordance with the provisions of the Securities Act. At September 30, 2017, the number of potential dilutive shares of the Company’s common stock into which the Series C debentures can be converted based upon the conversion provisions contained in the debenture is 952,381 The Company has also issued 4,356,460 3.5 60% or less 15,247,610 For the three months ended September 30, 2017 2016 Calculation of basic and diluted loss per share of common stock: Net loss attributable to common stockholders $ (2,005,555) $ (3,061,444) Denominator for basic and diluted weighted average shares of common stock 63,307,083 58,179,949 Basic and diluted loss per share of common stock $ (0.03) $ (0.05) Series C debentures were excluded from the fully diluted loss per share calculation for the three months ended September 30, 2017 because their inclusion is anti-dilutive. Series B and Series C debentures were excluded from the fully diluted loss per share calculation for the three months ended September 30, 2016 because their inclusion is anti-dilutive. In July 2017, the FASB issued Accounting Standards Update (“ASU”) No. 2017-11. “Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features, II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. ASU 2017-11 revises the guidance for instruments with down round features in Subtopic 815-40, Derivatives and Hedging – Contracts in Entity’s Own Equity, which is considered in determining whether an equity-linked financial instrument qualifies for a scope exception from derivative accounting. An entity still is required to determine whether instruments would be classified in equity under the guidance in Subtopic 815-40 in determining whether they qualify for that scope exception. If they do qualify, freestanding instruments with down round features are no longer classified as liabilities. ASU 2017-11 is effective for annual and interim periods beginning December 15, 2018, and early adoption is permitted, including adoption in an interim. ASU 2017-11 provides that upon adoption, an entity may apply this standard retrospectively to outstanding financial instruments with a down round feature by means of a cumulative-effect adjustment to the opening balance of retaining earnings in the fiscal year and interim period adoption. The Company is currently in the process of assessing the impact of this ASU on its financial statements. In March 2016, the FASB issued ASU No. 2016-09, “Stock Compensation (topic 718)”, which includes provisions intended to simplify various aspects related to how share-based payments are accounted for and presented in the financial statements. The standard is effective for annual periods beginning after December 15, 2016, with early adoption permitted. The adoption of this standard on July 1, 2017 did not have a material effect on the Company’s financial position, results of operations or cash flows.

Financial Condition

Financial Condition	3 Months Ended
	Sep. 30, 2017
Financial Condition Disclosure [Abstract]
Financial Condition Disclosure [Text Block]	Note 3 - Financial Condition The Company’s financial statements for the interim period ended September 30, 2017 have been prepared on a going concern basis, which contemplates the realization of assets and settlement of liabilities and commitments in the normal course of business. The Company has an accumulated deficit at September 30, 2017 of $ 77,134,246 13,512,240 Management believes that the Company’s existing cash resources are sufficient for its operations at the current rate of expenditures to continue through November 2018. However, management believes that the available funds are insufficient for the Company’s projected work, which is beyond normal pre-clinical development operations, leading towards an Investigational New Drug Application (IND) filing with the U.S. Food and Drug Administration (FDA), to continue through November 2018. The Company has engaged investment banks to advise it as to raising further funding as the Company progresses towards human clinical trials. The Company believes that it can adjust its business plan according to its available resources. Further, the Company believes that it will be able to raise additional funding at an opportune time as it progresses towards human clinical trials. However, the Company cannot provide assurance that its plans will not change or that changed circumstances will not result in the depletion of its capital resources more rapidly than it currently anticipates. Further, the Company cannot provide assurances that it will be able to raise additional funding in a timely manner, and if it can, that it will be on terms favorable for the Company’s current shareholders. The accompanying unaudited financial statements do not include any adjustments that may result from the outcome of such unidentified uncertainties. While the Company continues to incur significant operating losses with significant capital requirements, the Company has been able to finance its business through sale of its securities. The Company has in the past adjusted its priorities and goals in line with the cash on hand and capital availability. The Company believes it can adjust its priorities of drug development and its plan of operations as necessary, if it is unable to raise additional funds. The Company has sufficient capital to continue its business for more than one year, at the current rate of expenditure.

Related Party Transactions

Related Party Transactions	3 Months Ended
	Sep. 30, 2017
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	Note 4 - Related Party Transactions Related Parties Related parties with whom the Company had transactions are: Related Parties Relationship Anil R. Diwan Chairman, President, significant stockholder and Director Eugene Seymour CEO, significant stockholder, Director TheraCour Pharma, Inc. An entity owned and controlled by a significant stockholder Milton Boniuk, MD Director and significant stockholder For the three months ended September 30, September 30, 2017 2016 Property and Equipment During the reporting period, TheraCour Pharma, Inc. acquired property and equipment on behalf of the Company from third party vendors and sold such property and equipment, at cost, to the Company $ — $ 17,995 As of September 30, June 30, 2017 2017 Account Payable – Related Party Pursuant to an Exclusive License Agreement we entered into with TheraCour Pharma, Inc., (TheraCour), the Company was granted exclusive licenses in perpetuity for technologies developed by TheraCour for the virus types: HIV, HCV, Herpes, Asian (bird) flu, Influenza and rabies. In consideration for obtaining this exclusive license, we agreed: (1) that TheraCour can charge its costs (direct and indirect) plus no more than 30% of direct costs, as a development fee and such development fees shall be due and payable in periodic installments as billed, (2) we will pay $2,000 or actual costs each month, whichever is higher for other general and administrative expenses incurred by TheraCour on our behalf. Accounts payable due TheraCour Pharma Inc. on the reporting date was $ 818,783 $ 340,695 For the three months ended September 30, September 30, 2017 2016 Research and Development Costs Paid to Related Parties Development fees and other costs charged by and paid to TheraCour pursuant to an Exclusive License Agreement between TheraCour and the Company for the development of the Company’s drug pipeline. No royalties are due TheraCour from the Company at September 30, 2017 and June 30, 2017. $ 847,093 $ 861,616 As of September 30, June 30, 2017 2017 Debentures Payable to a Director Series C Convertible Debentures - Milton Boniuk $ 5,000,000 $ 5,000,000 As of September 30, June 30, 2017 2017 Debenture Interest Payable to a Director Coupon interest payable on $5,000,000 Series C Convertible Debentures and deferred. The deferred interest is paid out quarterly over the remaining term of the debenture commencing September 30, 2015: $ 125,000 $ 166,667 Coupon interest expense on the Series C Debentures to Dr. Milton Boniuk for the three months ended September 30, 2017 and 2016 was $ 125,000 125,000 Coupon interest expense on the Series B Debentures to Dr. Milton Boniuk for the three-months ended September 30, 2016 was $ 80,000

Property and Equipment

Property and Equipment	3 Months Ended
	Sep. 30, 2017
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	Note 5 - Property and Equipment September 30, June 30, 2017 2017 GMP Facility $ 7,996,402 $ 7,996,402 Land 260,000 260,000 Office Equipment 48,486 48,486 Furniture and Fixtures 5,607 5,607 Lab Equipment 5,496,499 5,466,066 Total Property and Equipment 13,806,994 13,776,561 Less Accumulated Depreciation (2,671,690) (2,505,501) Property and Equipment, Net $ 11,135,304 $ 11,271,060 Depreciation expense for the three months ended September 30, 2017 and 2016 was $ 166,189 163,286

Trademark and Patents

Trademark and Patents	3 Months Ended
	Sep. 30, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets Disclosure [Text Block]	Note 6 - Trademark and Patents September 30, June 30, 2017 2017 Trademarks and Patents $ 458,954 $ 458,954 Less Accumulated Amortization (77,824) (75,756) Trademarks and Patents, Net $ 381,130 $ 383,198 Amortization expense amounted to $ 2,068 2,067

Convertible Debentures and Deri

Convertible Debentures and Derivatives	3 Months Ended
	Sep. 30, 2017
Debt Disclosure [Abstract]
Debt Disclosure [Text Block]	Note 7 - Convertible Debentures and Derivatives Debentures - Series B The Series B debentures matured on February 1, 2017 120,000 The debt discount has been amortized to interest expense over the term of the debenture. The Company recognized amortization of the discount as an additional interest charge to “Discount on convertible debentures” for the three months ended September 30, 2016, in the amount of $ 213,872 The fair value of the compound embedded derivatives of the Series B Convertible Debenture at September 30, 2016 was $ 120,123 (82,907) Debenture - Series C On July 2, 2014 (the “Closing Date”), the Company accepted a subscription in the amount of $ 5,000,000 10 0.001 5.25 500,000 166,667 125,000 41,667 5.25 952,381 5.25 7 619,048 6.05 On July 2, 2014, in conjunction with the issuance of the Company’s Series C Convertible Debentures, the Company issued 187,000 1,645,606 1,152,297 1,152,297 1,879,428 The Company recognized amortization of this discount as an additional interest charge to “Discount on convertible debentures” in the amount of $ 239,351 189,590 September 30, June 30, 2017 2017 Proceeds $ 5,000,000 $ 5,000,000 Debt Discount: Series A Preferred (1,152,297) (1,152,297) Embedded derivative (1,879,428) (1,879,428) 1,968,275 1,968,275 Accumulated amortization of debt discount 2,227,229 1,987,878 Debenture payable - Series C, net $ 4,195,504 $ 3,956,153 The Company uses a lattice model that values the compound embedded derivatives of the Series C Convertible Debenture based on a probability weighted discounted cash flow model at September 30, 2017 and June 30, 2017. The following assumptions were used for the valuation of the compound embedded derivative at September 30 and June 30, 2017: ⋅ The balance of the Series C Convertible Debenture as of September 30, 2017 and June 30, 2017 is $ 5,000,000 ⋅ The underlying stock price was used as the fair value of the common stock; The stock price decreased to $ 1.14 6.05 1.35 6.05 ⋅ The projected annual volatility was based on the Company historical volatility: 1 year 9/30/17 53 % 6/30/17 60 % ⋅ An event of default would occur 0% of the time, increasing 1.00% per month to a maximum of 10% ⋅ The Holder would automatically convert the interest if the Company was not in default and its share value was equivalent to the cash value; ⋅ The Holder would automatically convert the debenture at maturity if the registration was effective and the Company was not in default. ⋅ The weighted cost of capital discount rate (based on the market value of the transaction at issuance) adjusted for changes in the risk free rate is 21.99 ⋅ Even though the shares are restricted the underlying assumption is that any restriction on resale will be removed either through registration or the passage of time at the time of issuance. The fair value of the compound embedded derivatives of the Series C Convertible Debenture at September 30, 2017 and June 30, 2017 was $ 20,094 32,213

Equity Transactions

Equity Transactions	3 Months Ended
	Sep. 30, 2017
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	Note 8 - Equity Transactions On July 21, 2015, the Board of Directors approved a new employment agreement with Dr. Anil Diwan, the Company’s President. Pursuant to the terms of the employment agreement, the Company’s Board of Directors authorized the issuance of 225,000 75,000 75,000 66,786 74,317 200,358 On July 21, 2015, the Board of Directors approved a new employment agreement with Dr. Eugene Seymour, the Company’s Chief Executive Officer. Pursuant to the terms of the employment agreement, the Company’s Board of Directors authorized the issuance of 225,000 75,000 75,000 66,786 74,317 200,358 For the three months ended September 30, 2017, the Company’s Board of Directors authorized the issuance of 7,716 25,227 Date Shares Value 7/31/2017 2,572 $ 8,242 8/31/2017 2,572 8,397 9/30/2017 2,572 8,588 7,716 $ 25,227 There is currently no market for the shares of Series A Preferred Stock and they can only be converted into shares of common stock upon a Change of Control of the Company as more fully described in the Certificate of Designation. The Company, therefore, estimated the fair value of the Series A Preferred stock granted to various employees and others on the date of grant. The Series A Preferred stock fair value is based on the greater of i) the converted value to common at a ratio of 1:3.5 a. The common stock price was in the range $ 1.35 1.40 b. The calculated weighted average number of shares of common stock in the period; c. A 26.63 d. The calculated weighted average number of total voting shares and the monthly shares representing voting rights of 12.27 12.30 e. The conversion value is based on an assumption for calculation purposes only of a Change of Control in 4 3.25 3.09 f. 32.18 31.85 59.78 58.33 1.55 1.46 In August 2017, the Scientific Advisory Board (SAB) was granted fully vested warrants to purchase 11,432 1.56 5,773 Expected life (year) 4 Expected volatility 55.56 % Expected annual rate of quarterly dividends 0.00 % Risk-free rate(s) 1.67 % For the three months ended September 30, 2017, the Company’s Board of Directors authorized the issuance of 20,062 27,000 For the three months ended September 30, 2017, the Company’s Board of Directors authorized the issuance of 8,358 11,250

Stock Warrants

Stock Warrants	3 Months Ended
	Sep. 30, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	Note 9 - Stock Warrants Stock Warrants Average Weighted Exercise Average Price Remaining Aggregate Number of per share Contractual Term Intrinsic Value Stock Warrants Shares ($) (years) ($) Outstanding and exercisable at June 30, 2017 6,673,860 $ 4.93 1.36 $ - Granted 11,432 1.56 3.83 - Outstanding and exercisable at September 30, 2017 6,685,292 $ 4.94 1.11 $ - Of the above warrants, 482,861 June 30, 2018 6,065,247 June 30, 2019 68,592 June 30, 2020 57,160 June 30, 2021 11,432 June 30, 2022

Fair Value Measurement

Fair Value Measurement	3 Months Ended
	Sep. 30, 2017
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Text Block]	Note 10 - Fair Value Measurement Fair value measurements At September 30, 2017 and June 30, 2017, the fair value of derivative liabilities is estimated using a lattice model that is based on the individual characteristics of our warrants, preferred and common stock, the derivative liability on the valuation date as well as assumptions for volatility, remaining expected life, risk-free interest rate and, in some cases, credit spread. The derivative liabilities are the only Level 3 fair value measures. Fair Value Measurements at September 30, 2017: (Level 1) (Level 2) (Level 3) Derivative liability – Series C debentures $ - - $ 20,094 Derivative liability – warrants - - 1,462,625 Total derivatives $ - $ - $ 1,482,719 Fair Value Measurements at June 30, 2017: (Level 1) (Level 2) (Level 3) Derivative liability – Series C debentures $ - - $ 32,213 Derivative liability – warrants - - 2,015,354 Total derivatives $ - $ - $ 2,047,567 In conjunction with the Company’s registered direct offerings of Units, consisting of the Company’s common stock and warrants, on September 12, 2013 and January 24, 2014 the Company issued 2,945,428 2,479,935 2,810,071 2,479,935 58,910 76,306 5,425,222 The Company accounts for stock purchase warrants as either equity instruments or derivative liabilities depending on the specific terms of the warrant agreements. Under applicable accounting guidance, stock warrants must be accounted for as derivative financial instruments if the warrants contain full-ratchet anti-dilution provisions, which preclude the warrants from being considered indexed to its own stock. The warrants described above contained a full-ratchet anti-dilution feature and are thus classified as a derivative liability. The Company used a lattice model to calculate the fair value of the derivative warrants based on a probability weighted discounted cash flow model. This model is based on future projections of the various potential outcomes. The features that were analyzed and incorporated into the model included the exercise and full reset features. The Warrants were valued as of September 30, 2017 and June 30, 2017 with the following assumptions: - The 5 5.25 6.05 - The stock price would fluctuate with the Company projected volatility. - The Holder would exercise the warrant as they become exercisable (effective registration at issuance) at target prices of the higher of 2 times 2 times - The next capital raise would fluctuate with an annual volatility. The projected volatility curve was based on historical volatilities of the Company for the valuation periods. 1 Year 9/30/17 53 % 6/30/17 60 % The primary factors driving the economic value of options are stock price; stock volatility; reset events and exercise behavior. Projections of these variables over the remaining term of the warrant are either derived or based on industry averages. Based on the above, a probability was assigned to each scenario for each future period, and the appropriate derivative value was determined for each scenario. The option value was then probability weighted and discounted to the present. Fair Value Measurement Using Significant Unobservable Inputs Derivative Derivative liability – liability – Series C warrant Beginning balance at July 1, 2017 $ 32,213 $ 2,015,354 Additions during the year - - Change in fair value (12,119) (552,729) Transfer in and/or out of Level 3 - - Balance at September 30, 2017 $ 20,094 $ 1,462,625

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Sep. 30, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	Note 11 - Commitments and Contingencies Legal Proceedings There are no pending legal proceedings against the Company to the best of the Company’s knowledge as of the date hereof and to the Company’s knowledge, no action, suit or proceeding has been threatened against the Company. Employment Agreements The Company and Dr. Diwan, President and Chairman of the Board of Directors, entered into an employment agreement effective July 1, 2015 for a term of three years. Dr. Diwan’s compensation would be $ 350,000 375,000 400,000 225,000 75,000 75,000 75,000 July 31, 2015 The Company and Dr. Seymour, the Company’s Chief Executive Officer and Director, entered into an employment agreement effective July 1, 2015, for a term of three years. Dr. Seymour’s compensation would be $ 350,000 375,000 400,000 225,000 On March 3, 2010, the Company entered into an employment agreement with Dr. Jayant Tatake to serve as Vice President of Research and Development. The employment agreement provides for a term of four years with a base salary of $ 150,000 26,786 35,715 26,786 35,715 On March 3, 2010, the Company entered into an employment agreement with Dr. Randall Barton to serve as Chief Scientific Officer. The employment agreement provided for a term of four years with a base salary of $ 150,000 35,715 35,715 On May 30, 2013, the Company entered into an Employment Agreement with Meeta Vyas to serve as its Chief Financial Officer. The employment agreement provided for a term of three years with a base salary of $ 9,000 2,572 10,800 License Agreements The Company is dependent upon its license agreement with TheraCour Pharma, Inc. (See Note 4). If the Company lost the right to utilize any of the proprietary information that is the subject of the TheraCour Pharma license agreement on which it depends, the Company will incur substantial delays and costs in development of its drug candidates.

Subsequent Events

Subsequent Events	3 Months Ended
	Sep. 30, 2017
Subsequent Events [Abstract]
Subsequent Events [Text Block]	Note 12 - Subsequent Events The Management of the Company has determined that there was a reportable subsequent event to be disclosed as follows: On November 13, 2017, the Registrant entered into a Debenture Redemption Agreement (the “Agreement”) with the Milton Boniuk IRA (the “Holder”), an entity controlled by Dr. Milton Boniuk , a Company Director , to redeem (the “Redemption”) its $5,000,000 Series C Convertible Debenture (the “Debenture”) for an aggregate of 5,500,000 shares of the Company’s $0.001 par value Common Stock (“Purchase Price”) comprising 5,000,000 shares for the principal of the Debenture and 500,000 for unpaid interest through June 30, 2018, the original maturity date of the Debenture. The price per share was equal to the closing price of the of the Registrant’s stock price on Friday, November 10, 2017 of one ($1.00) dollar per share. The Holder waived all early redemption payments provided for in the Debenture for consideration of 150,000 shares of the Company’s $0.001 par value Series A Convertible Preferred Stock. The Company did not incur placement agent fees in redemption of the Series C Convertible Debenture. The Company estimates that the redemption of the Series C Convertible Debenture permits the Company to retain approximately $5,500,000 of cash which would have been otherwise paid to the Holder.

Summary of Significant Accoun19

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Sep. 30, 2017
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation – Interim Financial Information The accompanying unaudited interim financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission for Interim Reporting. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim financial statements furnished reflect all adjustments (consisting of normal recurring accruals) that are, in the opinion of management, considered necessary for a fair presentation of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. The accompanying financial statements and the information included under the heading “Management’s Discussion and Analysis or Plan of Operation” should be read in conjunction with our Company’s audited financial statements and related notes included in our Company’s Form 10-K for the fiscal year ended June 30, 2017 filed with the SEC on September 28, 2017. For a summary of significant accounting policies, see the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2017 filed on September 28, 2017.
Earnings Per Share, Policy [Policy Text Block]	Net Loss per Common Share Basic net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock and potentially outstanding shares of common stock during the period to reflect the potential dilution that could occur from common shares issuable through stock options, warrants, convertible preferred stock, and convertible debentures. Potentially Outstanding Dilutive Common Shares For the For the Three Months Three Months Ended Ended September 30, 2017 September 30, 2016 Warrants 6,685,292 6,633,848 Total potentially outstanding dilutive common shares 6,685,292 6,633,848 Pursuant to the redemption provisions of the Company’s Series C Convertible Debenture (the “Series C Debenture”), the Company, at its sole option, shall have the right, but not the obligation, to repurchase the Debenture at any time prior to the Maturity Date (the “Redemption”). If the Company intends to repurchase the Debenture, and if the closing bid price of the common Stock is greater than $5.25 on the Redemption Date, unless the Holder, on or prior to the Redemption Date, elects to receive the “Redemption Payment”, as that term is defined herein, the Company shall pay to the Holder: (i) 952,381 shares of common stock in consideration of the exchange of the principal amount of the Debenture; and (ii) any and all accrued coupon interest. If on or prior to the Redemption Date, the Holder elects to receive the Redemption Payment, or the closing bid price of the Common Stock is less than $5.25, the Company shall issue to the Holder: (i) the principal amount of the Debenture; (ii) any accrued coupon interest; (iii) additional interest of 7% per annum for the period from the date of issuance of the Debenture to the Redemption Date; and (iv) warrants to purchase 619,048 shares of common stock which shall expire in three years from the date of issuance at an exercise price of $6.05 per share of common stock (the “Redemption Warrants”, and collectively with (i) – (iv), the “Redemption Payment”). The Company shall use its best efforts to register the shares underlying the Redemption Warrants under a “shelf” registration statement, provided same is available to the Company, in accordance with the provisions of the Securities Act. At September 30, 2017, the number of potential dilutive shares of the Company’s common stock into which the Series C debentures can be converted based upon the conversion provisions contained in the debenture is 952,381 The Company has also issued 4,356,460 3.5 60% or less 15,247,610 For the three months ended September 30, 2017 2016 Calculation of basic and diluted loss per share of common stock: Net loss attributable to common stockholders $ (2,005,555) $ (3,061,444) Denominator for basic and diluted weighted average shares of common stock 63,307,083 58,179,949 Basic and diluted loss per share of common stock $ (0.03) $ (0.05) Series C debentures were excluded from the fully diluted loss per share calculation for the three months ended September 30, 2017 because their inclusion is anti-dilutive. Series B and Series C debentures were excluded from the fully diluted loss per share calculation for the three months ended September 30, 2016 because their inclusion is anti-dilutive.
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Issued Accounting Pronouncements In July 2017, the FASB issued Accounting Standards Update (“ASU”) No. 2017-11. “Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features, II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. ASU 2017-11 revises the guidance for instruments with down round features in Subtopic 815-40, Derivatives and Hedging – Contracts in Entity’s Own Equity, which is considered in determining whether an equity-linked financial instrument qualifies for a scope exception from derivative accounting. An entity still is required to determine whether instruments would be classified in equity under the guidance in Subtopic 815-40 in determining whether they qualify for that scope exception. If they do qualify, freestanding instruments with down round features are no longer classified as liabilities. ASU 2017-11 is effective for annual and interim periods beginning December 15, 2018, and early adoption is permitted, including adoption in an interim. ASU 2017-11 provides that upon adoption, an entity may apply this standard retrospectively to outstanding financial instruments with a down round feature by means of a cumulative-effect adjustment to the opening balance of retaining earnings in the fiscal year and interim period adoption. The Company is currently in the process of assessing the impact of this ASU on its financial statements. In March 2016, the FASB issued ASU No. 2016-09, “Stock Compensation (topic 718)”, which includes provisions intended to simplify various aspects related to how share-based payments are accounted for and presented in the financial statements. The standard is effective for annual periods beginning after December 15, 2016, with early adoption permitted. The adoption of this standard on July 1, 2017 did not have a material effect on the Company’s financial position, results of operations or cash flows.

Summary of Significant Accoun20

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Sep. 30, 2017
Accounting Policies [Abstract]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	The following table shows the number of potentially outstanding dilutive common shares excluded from the diluted net loss per common share calculation, as they were anti-dilutive: Potentially Outstanding Dilutive Common Shares For the For the Three Months Three Months Ended Ended September 30, 2017 September 30, 2016 Warrants 6,685,292 6,633,848 Total potentially outstanding dilutive common shares 6,685,292 6,633,848 The following represents the basic and diluted per share calculations for loss from continuing operations: For the three months ended September 30, 2017 2016 Calculation of basic and diluted loss per share of common stock: Net loss attributable to common stockholders $ (2,005,555) $ (3,061,444) Denominator for basic and diluted weighted average shares of common stock 63,307,083 58,179,949 Basic and diluted loss per share of common stock $ (0.03) $ (0.05)

Related Party Transactions (Tab

Related Party Transactions (Tables)	3 Months Ended
	Sep. 30, 2017
Related Party Transactions [Abstract]
Schedule of Related Party Transactions [Table Text Block]	For the three months ended September 30, September 30, 2017 2016 Property and Equipment During the reporting period, TheraCour Pharma, Inc. acquired property and equipment on behalf of the Company from third party vendors and sold such property and equipment, at cost, to the Company $ — $ 17,995 As of September 30, June 30, 2017 2017 Account Payable – Related Party Pursuant to an Exclusive License Agreement we entered into with TheraCour Pharma, Inc., (TheraCour), the Company was granted exclusive licenses in perpetuity for technologies developed by TheraCour for the virus types: HIV, HCV, Herpes, Asian (bird) flu, Influenza and rabies. In consideration for obtaining this exclusive license, we agreed: (1) that TheraCour can charge its costs (direct and indirect) plus no more than 30% of direct costs, as a development fee and such development fees shall be due and payable in periodic installments as billed, (2) we will pay $2,000 or actual costs each month, whichever is higher for other general and administrative expenses incurred by TheraCour on our behalf. Accounts payable due TheraCour Pharma Inc. on the reporting date was $ 818,783 $ 340,695 For the three months ended September 30, September 30, 2017 2016 Research and Development Costs Paid to Related Parties Development fees and other costs charged by and paid to TheraCour pursuant to an Exclusive License Agreement between TheraCour and the Company for the development of the Company’s drug pipeline. No royalties are due TheraCour from the Company at September 30, 2017 and June 30, 2017. $ 847,093 $ 861,616 As of September 30, June 30, 2017 2017 Debentures Payable to a Director Series C Convertible Debentures - Milton Boniuk $ 5,000,000 $ 5,000,000 As of September 30, June 30, 2017 2017 Debenture Interest Payable to a Director Coupon interest payable on $5,000,000 Series C Convertible Debentures and deferred. The deferred interest is paid out quarterly over the remaining term of the debenture commencing September 30, 2015: $ 125,000 $ 166,667

Property and Equipment (Tables)

Property and Equipment (Tables)	3 Months Ended
	Sep. 30, 2017
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment [Table Text Block]	Property and equipment, stated at cost, less accumulated depreciation consisted of the following: September 30, June 30, 2017 2017 GMP Facility $ 7,996,402 $ 7,996,402 Land 260,000 260,000 Office Equipment 48,486 48,486 Furniture and Fixtures 5,607 5,607 Lab Equipment 5,496,499 5,466,066 Total Property and Equipment 13,806,994 13,776,561 Less Accumulated Depreciation (2,671,690) (2,505,501) Property and Equipment, Net $ 11,135,304 $ 11,271,060

Trademark and Patents (Tables)

Trademark and Patents (Tables)	3 Months Ended
	Sep. 30, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Finite-Lived Intangible Assets [Table Text Block]	Trademark and patents, stated at cost, less accumulated amortization consisted of the following: September 30, June 30, 2017 2017 Trademarks and Patents $ 458,954 $ 458,954 Less Accumulated Amortization (77,824) (75,756) Trademarks and Patents, Net $ 381,130 $ 383,198

Convertible Debentures and De24

Convertible Debentures and Derivatives (Tables)	3 Months Ended
	Sep. 30, 2017
Series C Debentures [Member]
Schedule of Long-term Debt Instruments [Table Text Block]	The following represents the balance of the Debenture payable – Series C, net of discount at September 30, 2017 and June 30, 2017: September 30, June 30, 2017 2017 Proceeds $ 5,000,000 $ 5,000,000 Debt Discount: Series A Preferred (1,152,297) (1,152,297) Embedded derivative (1,879,428) (1,879,428) 1,968,275 1,968,275 Accumulated amortization of debt discount 2,227,229 1,987,878 Debenture payable - Series C, net $ 4,195,504 $ 3,956,153

Equity Transactions (Tables)

Equity Transactions (Tables)	3 Months Ended
	Sep. 30, 2017
Schedule of Stockholders Equity [Table Text Block]	The Company estimated the fair value of the warrants granted to the Scientific Advisory Board on the date of grant using the Black-Scholes Option-Pricing Model with the following weighted-average assumptions: Expected life (year) 4 Expected volatility 55.56 % Expected annual rate of quarterly dividends 0.00 % Risk-free rate(s) 1.67 %
Series A Preferred Stock [Member]
Schedule Of Fair Value Of Stock Classified By Issuance Date [Table Text Block]	The fair value of the Series A Preferred stock was the following for the dates indicated: Date Shares Value 7/31/2017 2,572 $ 8,242 8/31/2017 2,572 8,397 9/30/2017 2,572 8,588 7,716 $ 25,227

Stock Warrants (Tables)

Stock Warrants (Tables)	3 Months Ended
	Sep. 30, 2017
Stock Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	Average Weighted Exercise Average Price Remaining Aggregate Number of per share Contractual Term Intrinsic Value Stock Warrants Shares ($) (years) ($) Outstanding and exercisable at June 30, 2017 6,673,860 $ 4.93 1.36 $ - Granted 11,432 1.56 3.83 - Outstanding and exercisable at September 30, 2017 6,685,292 $ 4.94 1.11 $ -

Fair Value Measurement (Tables)

Fair Value Measurement (Tables)	3 Months Ended
	Sep. 30, 2017
Fair Value Disclosures [Abstract]
Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]	At September 30, 2017 and June 30, 2017 the estimated fair values of the liabilities measured on a recurring basis are as follows: Fair Value Measurements at September 30, 2017: (Level 1) (Level 2) (Level 3) Derivative liability – Series C debentures $ - - $ 20,094 Derivative liability – warrants - - 1,462,625 Total derivatives $ - $ - $ 1,482,719 Fair Value Measurements at June 30, 2017: (Level 1) (Level 2) (Level 3) Derivative liability – Series C debentures $ - - $ 32,213 Derivative liability – warrants - - 2,015,354 Total derivatives $ - $ - $ 2,047,567
Schedule Of Projected Annual Volatility [Table Text Block]	The projected annual volatility for the valuation dates are: 1 Year 9/30/17 53 % 6/30/17 60 %
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	The following tables present the activity for liabilities measured at estimated fair value using unobservable inputs for the three months ended September 30, 2017: Fair Value Measurement Using Significant Unobservable Inputs Derivative Derivative liability – liability – Series C warrant Beginning balance at July 1, 2017 $ 32,213 $ 2,015,354 Additions during the year - - Change in fair value (12,119) (552,729) Transfer in and/or out of Level 3 - - Balance at September 30, 2017 $ 20,094 $ 1,462,625

Organization and Nature of Bu28

Organization and Nature of Business (Details Textual) - USD ($)	1 Months Ended	3 Months Ended
	Feb. 15, 2010	Sep. 30, 2017	Jun. 30, 2017
Product Information [Line Items]
Entity Incorporation, Date Of Incorporation		Jul. 25, 2000
Business Acquisition, Name of Acquired Entity		Edot-com.com, Inc.
Business Acquisition, Date of Acquisition Agreement		May 12, 2005
Common stock, shares issued		63,335,194	63,306,774
ECMM [Member]
Product Information [Line Items]
Common Stock Shares Issued Pro rata Basis		4,000
Stock Issued During Period, Shares, New Issues		80,000,000
Common stock, shares issued		100,000,000
Business Acquisition, Percentage of Voting Interests Acquired		80.00%
Series A Preferred Stock [Member]
Product Information [Line Items]
Preferred stock, shares issued	2,000,000
Preferred stock, value	$ 2,000
Stockholders' Equity, Reverse Stock Split	(adjusted for the 3.5 to 1 reverse split)

Summary of Significant Accoun29

Summary of Significant Accounting Policies (Details) - shares	3 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Accounting Policies [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	6,685,292	6,633,848
Warrants [Member]
Accounting Policies [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	6,685,292	6,633,848

Summary of Significant Accoun30

Summary of Significant Accounting Policies (Details 1) - USD ($)	3 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Calculation of basic and diluted loss per share of common stock:
Net loss attributable to common stockholders	$ (2,005,555)	$ (3,061,444)
Denominator for basic and diluted weighted average shares of common stock	63,307,083	58,179,949
Basic and diluted loss per share of common stock	$ (0.03)	$ (0.05)

Summary of Significant Accoun31

Summary of Significant Accounting Policies (Details Textual) - $ / shares	3 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Jun. 30, 2017
Accounting Policies [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	6,685,292	6,633,848
Debt Instrument, Redemption, Description	the Company, at its sole option, shall have the right, but not the obligation, to repurchase the Debenture at any time prior to the Maturity Date (the Redemption). If the Company intends to repurchase the Debenture, and if the closing bid price of the common Stock is greater than $5.25 on the Redemption Date, unless the Holder, on or prior to the Redemption Date, elects to receive the Redemption Payment, as that term is defined herein, the Company shall pay to the Holder: (i) 952,381 shares of common stock in consideration of the exchange of the principal amount of the Debenture; and (ii) any and all accrued coupon interest. If on or prior to the Redemption Date, the Holder elects to receive the Redemption Payment, or the closing bid price of the Common Stock is less than $5.25, the Company shall issue to the Holder: (i) the principal amount of the Debenture; (ii) any accrued coupon interest; (iii) additional interest of 7% per annum for the period from the date of issuance of the Debenture to the Redemption Date; and (iv) warrants to purchase 619,048 shares of common stock which shall expire in three years from the date of issuance at an exercise price of $6.05 per share of common stock (the Redemption Warrants, and collectively with (i) (iv), the Redemption Payment). The Company shall use its best efforts to register the shares underlying the Redemption Warrants under a shelf registration statement, provided same is available to the Company, in accordance with the provisions of the Securities Act.
Series A Convertible Preferred Stock [Member]
Accounting Policies [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 3.5
Convertible Preferred Stock, Terms of Conversion	60% or less
Preferred Stock, Shares Issued	4,356,460		4,348,744
Common Stock [Member] | Series C Convertible Debentures [Member]
Accounting Policies [Line Items]
Debt Conversion, Converted Instrument, Shares Issued	952,381
Series A converteble preferred shares [Member]
Accounting Policies [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	15,247,610

Financial Condition (Details Te

Financial Condition (Details Textual) - USD ($)	Sep. 30, 2017	Jun. 30, 2017	Sep. 30, 2016	Jun. 30, 2016
Financial Condition [Line Items]
Cash and cash equivalents	$ 13,512,240	$ 15,099,461	$ 21,912,927	$ 24,162,185
Retained Earnings (Accumulated Deficit)	$ (77,134,246)	$ (75,128,691)

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)	3 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Jun. 30, 2017	Jul. 02, 2014
Research and development	$ 1,155,228	$ 1,452,137
Series C Convertible Debenture [Member]
Due to Related Parties	5,000,000		$ 5,000,000
Debenture Interest Payable to a Director	125,000		166,667	$ 166,667
TheraCour Pharma, Inc [Member]
Net Account Payable to related party	818,783		$ 340,695
Research and development	847,093	861,616
Property, Plant and Equipment, Additions	$ 0	$ 17,995

Related Party Transactions (D34

Related Party Transactions (Details Textual) - USD ($)	3 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Related Party Transaction [Line Items]
Related Party Transaction, Description of Transaction	charge its costs (direct and indirect) plus no more than 30% of direct costs
Other General and Administrative Expense	$ 2,000
Series C Convertible Debenture [Member]
Related Party Transaction [Line Items]
Debt Instrument, Face Amount	5,000,000
Series C Convertible Debenture [Member] | Dr. Boniuk [Member]
Related Party Transaction [Line Items]
Interest Expense, Debt	80,000
Series B Debentures [Member] | Dr. Boniuk [Member]
Related Party Transaction [Line Items]
Interest Expense, Debt	$ 125,000	$ 125,000

Property and Equipment (Details

Property and Equipment (Details) - USD ($)	Sep. 30, 2017	Jun. 30, 2017
Property, Plant and Equipment [Line Items]
GMP Facility	$ 7,996,402	$ 7,996,402
Land	260,000	260,000
Office Equipment	48,486	48,486
Furniture and Fixtures	5,607	5,607
Lab Equipment	5,496,499	5,466,066
Total Property and Equipment	13,806,994	13,776,561
Less Accumulated Depreciation	(2,671,690)	(2,505,501)
Property and Equipment, Net	$ 11,135,304	$ 11,271,060

Property and Equipment (Detai36

Property and Equipment (Details Textual) - USD ($)	3 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Property, Plant and Equipment [Line Items]
Depreciation	$ 166,189	$ 163,286

Trademark and Patents (Details)

Trademark and Patents (Details) - USD ($)	Sep. 30, 2017	Jun. 30, 2017
Trademarks And Patents [Line Items]
Trademarks and Patents	$ 458,954	$ 458,954
Less Accumulated Amortization	(77,824)	(75,756)
Trademarks and Patents, Net	$ 381,130	$ 383,198

Trademark and Patents (Details

Trademark and Patents (Details Textual) - USD ($)	3 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Trademarks And Patents [Line Items]
Amortization	$ 2,068	$ 2,067
Trademark and Patents [Member]
Trademarks And Patents [Line Items]
Amortization	$ 2,068	$ 2,067

Convertible Debentures and De39

Convertible Debentures and Derivatives (Details) - Series C Debentures [Member] - USD ($)	3 Months Ended	12 Months Ended
	Sep. 30, 2017	Jun. 30, 2017
Proceeds	$ 5,000,000	$ 5,000,000
Net Proceeds From Issuance Of Debt	1,968,275	1,968,275
Accumulated amortization of debt discount	2,227,229	1,987,878
Debenture payable - Series C, net	4,195,504	3,956,153
Embedded Derivative Financial Instruments [Member]
Debt Discount	(1,879,428)	(1,879,428)
Series A Preferred [Member]
Debt Discount	$ (1,152,297)	$ (1,152,297)

Convertible Debentures and De40

Convertible Debentures and Derivatives (Details Textual) - USD ($)	Jul. 02, 2014	Sep. 30, 2017	Sep. 30, 2016	Jun. 30, 2017
Debt Instrument [Line Items]
Common stock, par value (in dollars per share)		$ 0.001		$ 0.001
Interest Paid, Net		$ 166,667	$ 286,667
Derivative, Gain (Loss) On Derivative, Net		$ 564,848	13,291
Series B Convertible Debentures [Member]
Debt Instrument [Line Items]
Amortization of Debt Discount (Premium)			213,872
Derivative Liability, Noncurrent			120,123
Interest Paid, Net			120,000
Debt Instrument, Maturity Date		Feb. 1, 2017
Derivative, Gain (Loss) On Derivative, Net			(82,907)
Series A Convertible Preferred Stock [Member]
Debt Instrument [Line Items]
Amortization of Debt Discount (Premium)		$ 239,351	189,590
Debt Conversion, Converted Instrument, Shares Issued	187,000
Proceeds from Convertible Debt	$ 1,645,606
Repayments of Other Debt	1,152,297
Debt Instrument, Unamortized Discount	1,152,297
Debt Conversion, Converted Instrument, Amount	$ 1,879,428
Series C Convertible Debenture [Member]
Debt Instrument [Line Items]
Common stock, par value (in dollars per share)	$ 0.001
Debt Instrument, Convertible, Conversion Price	$ 5.25
Debt Instrument, Interest Rate, Stated Percentage	10.00%
Debt Instrument, Convertible, Carrying Amount of Equity Component	$ 5,000,000
Redemption On Debentures	952,381
Warrants to purchase of Common Stock	619,048
Common stock exercise price	$ 6.05
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 6.05		$ 6.05
Long-term Debt, Excluding Current Maturities, Total		$ 5,000,000		$ 5,000,000
Share Price		$ 1.14		$ 1.35
Debt Instrument, Debt Default, Description of Violation or Event of Default		An event of default would occur 0% of the time, increasing 1.00% per month to a maximum of 10%		An event of default would occur 0% of the time, increasing 1.00% per month to a maximum of 10%;
Projected Redemption Percentage Of Time		53.00%		60.00%
Weighted Average Discount Rate, Percent		21.99%
Closing Common Stock Bid Price	$ 5.25
Additional Interest Rate For Warrants	7.00%
Interest Payable	$ 166,667	$ 125,000		$ 166,667
Debt Instrument, Periodic Payment, Interest	125,000
Common Stock Value Issued For Debt Instrument Periodic Interest Payment			$ 41,667
Series C Convertible Debenture [Member] | Embedded Derivative Financial Instruments [Member]
Debt Instrument [Line Items]
Derivative Liability, Noncurrent		$ 20,094		$ 32,213
Series C Convertible Debenture [Member] | Debenture Interest Paid [Member]
Debt Instrument [Line Items]
Interest Payable	$ 500,000

Equity Transactions (Details)

Equity Transactions (Details) - Series A Preferred Stock [Member]	3 Months Ended
	Sep. 30, 2017USD ($)shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross | shares	7,716
Stock Issued During Period, Value, Share-based Compensation, Gross | $	$ 25,227
Issuance Date One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross | shares	2,572
Stock Issued During Period, Value, Share-based Compensation, Gross | $	$ 8,242
Issuance Date Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross | shares	2,572
Stock Issued During Period, Value, Share-based Compensation, Gross | $	$ 8,397
Issuance Date Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross | shares	2,572
Stock Issued During Period, Value, Share-based Compensation, Gross | $	$ 8,588

Equity Transactions (Details 1)

Equity Transactions (Details 1) - Scientific Advisory Board [Member]	3 Months Ended
	Sep. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life (year)	4 years
Expected volatility	55.56%
Expected annual rate of quarterly dividends	0.00%
Risk-free rate(s)	1.67%

Equity Transactions (Details Te

Equity Transactions (Details Textual) - USD ($)	1 Months Ended	3 Months Ended		12 Months Ended
	Aug. 31, 2017	Sep. 30, 2017	Sep. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Jul. 21, 2015
Class of Stock [Line Items]
Employee Benefits and Share-based Compensation		$ 25,227
Warrant [Member]
Class of Stock [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 1.56
Warrant [Member] | August 2019
Class of Stock [Line Items]
Number Of Common Stock To Be Issued Upon Conversion Of Warrants	11,432
Warrant [Member] | November 2019
Class of Stock [Line Items]
Number Of Common Stock To Be Issued Upon Conversion Of Warrants		5,773
Director [Member]
Class of Stock [Line Items]
Share-based Compensation, Total		$ 11,250
Restricted common stock authorized for interest payable		8,358
President [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized						225,000
Share-based Compensation, Total		$ 66,786	$ 74,317
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options		200,358
President [Member] | Share-based Compensation Award, Tranche One [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares					75,000
President [Member] | Share-based Compensation Award, Tranche Two [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares				75,000
Chief Executive Officer [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized						225,000
Share-based Compensation, Total		66,786	$ 74,317
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options		200,358
Chief Executive Officer [Member] | Share-based Compensation Award, Tranche One [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares					75,000
Chief Executive Officer [Member] | Share-based Compensation Award, Tranche Two [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares				75,000
Series A Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Stock Issued During Period, Value, Issued For Services		$ 27,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period		7,716
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Conversion of Stock, Description		the converted value to common at a ratio of 1:3.5
Share Based Compensation Arrangement By Share Based Payment Award, Voting Rights, Percentage		26.63%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term		4 years
Series A Preferred Stock [Member] | Minimum [Member]
Class of Stock [Line Items]
Share Price		$ 1.35
Share Based Compensation Arrangement By Share Based Payment Award, Voting Rights, Percentage		12.27%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term		3 years 3 months
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Discount for Postvesting Restrictions		32.18%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate		59.78%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate		1.55%
Series A Preferred Stock [Member] | Maximum [Member]
Class of Stock [Line Items]
Share Price		$ 1.40
Share Based Compensation Arrangement By Share Based Payment Award, Voting Rights, Percentage		12.30%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term		3 years 1 month 2 days
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Discount for Postvesting Restrictions		31.85%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate		58.33%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate		1.46%
Series A Preferred Stock [Member] | Employee Compensations [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized		20,062

Stock Warrants (Details)

Stock Warrants (Details) - Stock Warrants [Member] - USD ($)	3 Months Ended	12 Months Ended
	Sep. 30, 2017	Jun. 30, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Outstanding	6,673,860
Number of Shares, Granted	11,432
Number of Shares, Outstanding	6,685,292
Weighted Average Exercise Price per share, Outstanding (dollars per share)	$ 4.93
Weighted Average Exercise Price per share, Granted (dollars per share)	1.56
Weighted Average Exercise Price per share, Outstanding (dollars per share)	$ 4.94
Weighted Average Remaining Contractual Term (years), Granted	3 years 9 months 29 days
Weighted Average Remaining Contractual Term (years), Outstanding	1 year 1 month 10 days	1 year 4 months 10 days
Aggregate Intrinsic Value, Outstanding (in dollars)	$ 0
Aggregate Intrinsic Value, Granted (in dollars)	0
Aggregate Intrinsic Value, Outstanding (in dollars)	$ 0

Stock Warrants (Details Textual

Stock Warrants (Details Textual)	3 Months Ended
	Sep. 30, 2017shares
June 30, 2018 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Exercisable	482,861
Warrants Expiration Date	Jun. 30, 2018
June 30, 2019 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Exercisable	6,065,247
Warrants Expiration Date	Jun. 30, 2019
June 30 2022 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Exercisable	11,432
Warrants Expiration Date	Jun. 30, 2022
June 30, 2020 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Exercisable	68,592
Warrants Expiration Date	Jun. 30, 2020
June 30, 2021 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Exercisable	57,160
Warrants Expiration Date	Jun. 30, 2021

Fair Value Measurement (Details

Fair Value Measurement (Details) - USD ($)	Sep. 30, 2017	Jun. 30, 2017
Warrant [Member]
Derivative Liability, Noncurrent	$ 1,462,625	$ 2,015,354
Fair Value, Inputs, Level 1 [Member]
Derivative Liability, Noncurrent	0	0
Fair Value, Inputs, Level 1 [Member] | Derivative liability - Series C debentures [Member]
Derivative Liability, Noncurrent	0	0
Fair Value, Inputs, Level 1 [Member] | Warrant [Member]
Derivative Liability, Noncurrent	0	0
Fair Value, Inputs, Level 2 [Member]
Derivative Liability, Noncurrent	0	0
Fair Value, Inputs, Level 2 [Member] | Derivative liability - Series C debentures [Member]
Derivative Liability, Noncurrent	0	0
Fair Value, Inputs, Level 2 [Member] | Warrant [Member]
Derivative Liability, Noncurrent	0	0
Fair Value, Inputs, Level 3 [Member]
Derivative Liability, Noncurrent	1,482,719	2,047,567
Fair Value, Inputs, Level 3 [Member] | Derivative liability - Series C debentures [Member]
Derivative Liability, Noncurrent	20,094	32,213
Fair Value, Inputs, Level 3 [Member] | Warrant [Member]
Derivative Liability, Noncurrent	$ 1,462,625	$ 2,015,354

Fair Value Measurement (Detai47

Fair Value Measurement (Details 1)	3 Months Ended
	Sep. 30, 2017
One year ended 9/30/2017
Fair Value Assumptions, Expected Volatility Rate	53.00%
One Year Ended 6/30/2017
Fair Value Assumptions, Expected Volatility Rate	60.00%

Fair Value Measurement (Detai48

Fair Value Measurement (Details 2)	3 Months Ended
	Sep. 30, 2017USD ($)
Derivative liability - Series C debentures [Member]
Beginning balance	$ 32,213
Additions during the year	0
Change in fair value	(12,119)
Transfer in and/or out of Level 3	0
Ending Balance	20,094
Warrant [Member]
Beginning balance	2,015,354
Additions during the year	0
Change in fair value	(552,729)
Transfer in and/or out of Level 3	0
Ending Balance	$ 1,462,625

Fair Value Measurement (Detai49

Fair Value Measurement (Details Textual) - $ / shares	1 Months Ended
	Jan. 24, 2014	Sep. 12, 2013	Sep. 30, 2017
Class of Warrant or Right, Outstanding	2,479,935	2,810,071
Warrants Issued	2,479,935	2,945,428
Placement Agents [Member]
Warrants Issued	76,306	58,910
Warrant Expiration Term	5 years	5 years
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 6.05	$ 5.25
Scientific Advisory Board [Member]
Class of Warrant or Right, Outstanding			5,425,222

Commitments and Contingencies (

Commitments and Contingencies (Details Textual) - USD ($)	1 Months Ended			3 Months Ended	12 Months Ended
	Jan. 31, 2015	May 30, 2013	Mar. 31, 2010	Sep. 30, 2017	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2015	Feb. 15, 2010
Commitments and Contingencies [Line Items]
Common stock, shares issued				63,335,194	63,306,774
Series A Preferred Stock [Member]
Commitments and Contingencies [Line Items]
Preferred stock, shares issued								2,000,000
Chief Executive Officer [Member]
Commitments and Contingencies [Line Items]
Deferred Compensation Bonus Paid					$ 75,000	$ 75,000
Chief Executive Officer [Member] | Share-based Compensation Award, Tranche One [Member]
Commitments and Contingencies [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares						75,000
Chief Executive Officer [Member] | Deferred Bonus [Member]
Commitments and Contingencies [Line Items]
Deferred Compensation Arrangement with Individual, Cash Award Granted, Amount					312,015
Chief Executive Officer [Member] | Year One [Member]
Commitments and Contingencies [Line Items]
Deferred Compensation Arrangement with Individual, Compensation Expense				$ 350,000
Chief Executive Officer [Member] | Year Two [Member]
Commitments and Contingencies [Line Items]
Deferred Compensation Arrangement with Individual, Compensation Expense				375,000
Chief Executive Officer [Member] | Year Three [Member]
Commitments and Contingencies [Line Items]
Deferred Compensation Arrangement with Individual, Compensation Expense				$ 400,000
Chief Executive Officer [Member] | Series A Preferred Stock [Member]
Commitments and Contingencies [Line Items]
Deferred Compensation Arrangement with Individual, Shares Authorized for Issuance				225,000
Chief Scientific Officer [Member]
Commitments and Contingencies [Line Items]
Common stock, shares issued			35,715
Additional Common Stock Shares Issued			35,715
Increase In Base Salary			$ 150,000
President [Member]
Commitments and Contingencies [Line Items]
Deferred Compensation Bonus Paid					$ 75,000	$ 75,000
President [Member] | Share-based Compensation Award, Tranche One [Member]
Commitments and Contingencies [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares						75,000
President [Member] | Year One [Member]
Commitments and Contingencies [Line Items]
Deferred Compensation Arrangement with Individual, Compensation Expense				$ 350,000
President [Member] | Year One [Member] | Share-based Compensation Award, Tranche One [Member]
Commitments and Contingencies [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares							75,000
President [Member] | Year Two [Member]
Commitments and Contingencies [Line Items]
Deferred Compensation Arrangement with Individual, Compensation Expense				375,000
President [Member] | Year Two [Member] | Share-based Compensation Award, Tranche One [Member]
Commitments and Contingencies [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares						75,000
President [Member] | Year Three [Member]
Commitments and Contingencies [Line Items]
Deferred Compensation Arrangement with Individual, Compensation Expense				$ 400,000
President [Member] | Year Three [Member] | Share-based Compensation Award, Tranche One [Member]
Commitments and Contingencies [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares					75,000
President [Member] | Series A Preferred Stock [Member]
Commitments and Contingencies [Line Items]
Deferred Compensation Arrangement with Individual, Shares Authorized for Issuance				225,000
Vice President [Member]
Commitments and Contingencies [Line Items]
Common stock, shares issued			35,715
Additional Common Stock Shares Issued			35,715
Increase In Base Salary			$ 150,000
Vice President [Member] | Series A Preferred Stock [Member]
Commitments and Contingencies [Line Items]
Preferred stock, shares issued			26,786
Additional Preferred Stock Shares Issued			26,786
Chief Financial Officer [Member]
Commitments and Contingencies [Line Items]
Increase In Base Salary	$ 10,800	$ 9,000
Chief Financial Officer [Member] | Series A Convertible Preferred Stock [Member]
Commitments and Contingencies [Line Items]
Preferred stock, shares issued		2,572

Subsequent Events (Details Text

Subsequent Events (Details Textual) - USD ($)	Nov. 13, 2017	Sep. 30, 2017	Jun. 30, 2017
Subsequent Event [Line Items]
Common Stock, Par Or Stated Value Per Share		$ 0.001	$ 0.001
Subsequent Event [Member]
Subsequent Event [Line Items]
Common Stock, Par Or Stated Value Per Share	$ 0.001
Debt Instrument, Convertible, Conversion Price	$ 1
Debt Conversion, Original Debt, Amount	$ 5,000,000
Cash	$ 5,500,000
Subsequent Event [Member] | Series A Preferred Stock [Member]
Subsequent Event [Line Items]
Preferred Stock, Par Value (In Dollars Per Share)	$ 0.001
Debt Conversion, Converted Instrument, Shares Issued	150,000
Subsequent Event [Member] | Common Stock [Member]
Subsequent Event [Line Items]
Debt Conversion, Converted Instrument, Shares Issued	5,500,000
Subsequent Event [Member] | Conversion For Principal [Member]
Subsequent Event [Line Items]
Debt Conversion, Converted Instrument, Shares Issued	5,000,000
Subsequent Event [Member] | Conversion For Unpaid Interest [Member]
Subsequent Event [Line Items]
Debt Conversion, Converted Instrument, Shares Issued	500,000